C-7UTSEndogena Therapeutics
endogenous regeneration, small molecules, stem/progenitor cells
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-7UTS
C-7UTSC-7UTSendogenous regeneration, small molecules, stem/progenitor cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Endogena Therapeutics has developed a novel approach to regenerative medicine that’s not only scientifically compelling, but practical. Endogena’s technology unlocks the body’s own stem cells for controlled tissue repair by small molecules. Its products use a dosing schedule that could move easily into the system already in place for intravitreal injections. CEO Matthias Steger, PhD, MBA, sat down with retina specialist Firas Rahhal, MD, to discuss the Endogena approach in depth. They also discuss the compelling results seen so far in both animal models and in patients. The company’s lead candidate is being developed to treat retinitis pigmentosa. The product has received Orphan Drug and Fast Track Designation from the FDA and is moving through Phase IIa clinical trials. Dr. Steger says the company expects to have data to share in early 2024. It’s also submitting an investigational new drug (IND) application for an age-related macular degeneration treatment later this month. Listen
We have conversations this week with Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rudolph Besserve, CEO, and Georges Rawadi, chief of biotech studio development at eureKARE; and Geoff Hsu, Biotech Growth Trust portfolio manager. Chapters: 02:30 - Labiotech.eu news 05:10 - Endogena Therapeutics 21:00 - eureKARE 33:46 - Deep Science Ventures 47:44 Biotech Growth Trust ➡ Listen to all Beyond Biotech episodes here: https://www.youtube.com/playlist?list... ➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc ➡ Get more biotech news: Official site: https://bit.ly/3OJgYzi Linkedin: https://www.linkedin.com/company/5312453 Twitter: https://twitter.com/Labiotech_eu Facebook: https://www.facebook.com/Labiotech.eu Instagram: https://www.instagram.com/labiotech.eu/ About Labiotech.eu: Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth ana
This is an open-label, multiple ascending dose study to evaluate the safety, tolerability, and efficacy of EA-2353 in subjects with RP. Unilateral intravitreal injections (IVT) will be administered into the subject's Study Eye. There will be up to 4 cohorts.
How can we reach longevity escape velocity in your lifetime? Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital Program & apply to join: https://foresight.org/biotech-health-extension-program/ Nikolina Lauc | Co-Founder & CEO - GlycanAge GlycanAge was founded on a promise that “health care” should start with us caring about our health before we encounter a particular problem. Disease starts on a molecular level decades before we are currently addressing it, while the majority of modern disease is preventable and the earliest molecular signal is biological ageing. GlycanAge allows you to measure & influence your longevity by looking at an entirely new part of biology. Glycan biomarkers uniquely encapsulate genetic, epigenetic and environmental factors driving longevity for every human. Michael Greve Together with his brother Matthias, he created numerous ventures including lastminute.de and turned it into the largest last-minute travel site in Germany. Mos
Oversubscribed Series A-1 funding round completed – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Oversubscribed Series A-1 funding round completed Endogena Therapeutics closed today their first round of Series A financing, which was capped at $8 million. This first round of Series A financing was led by existing investors, Rejuveron Life Sciences AG and DEFTA Partners, with new investors joining the syndicate. Matthias Steger, CEO of Endogena, said: “This Series A-1
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % This section contains press releases and other materials from thi … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
PharmiWeb.com – Thank you 1998 – 2026 AFTER TWENTY–EIGHT YEARS Thank you. Thank you for building PharmiWeb.com Since 1998, this community has helped people find opportunities, build careers, and connect across the industry. As we close this chapter, we do so with gratitude and pride in what we created together. For everyone who found an opportunity here, from entry-level roles to VP positions , and everything in between. And for every advertiser, partner, reader, and every member of the PharmiWeb team since 1998. We were there at the beginning of the dot-com era, even beating
Endogena Therapeutics - Human Resources Operations | The Org Platform Enrich Pricing Log in Sign up Endogena Therapeutics Teams Human Resources Operations Unverified Human Resources Operations 2 people · 0 jobs This department manages employee relations, recruitment, and operational support to enhance organizational effectiveness. People ( 2 ) Christiane Hyvert People & Culture, Operations CH Christiane Hyvert People & Culture Business Partner, Operations Manager Jobs ( 0 ) No jobs in this team Other teams View all teams Advisory Team 9 people · 0 jobs GS 5 Leadership Team 1 person ·
Stream News | Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas by Foundation Fighting Blindness | Listen online for free on SoundCloud SoundCloud JavaScript is disabled You need to enable JavaScript to use SoundCloud Show me how to enable it News | Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas by Foundation Fighting Blindness published on 2022-07-14T13:41:37Z The emerging treatment is gene-agnostic. Users who like News | Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retin
Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Two scientific posters were presented on May 8th at ARVO 2024 in Seattle, Washington, US Zürich, Switzerland, May 8, 2024 Two scientific posters were presented on May 8 th at ARVO 2024 in Seattle, Washington, US, with the respective poster titles: “The promotion of visual function regeneration by intravitreal administration of EA-23
Endogena Receives FDA Fast Tract Designation for RP | OBN Categories Breaking News Industry News Ophthalmic Blog Ophthalmic Research News Write for Us Spotlight TV Ophthalmology Glossary Subscribe Home Breaking News Endogena Therapeutics Receives FDA Fast Track Designation for Treatment of Retinitis Pigmentosa Endogena Therapeutics Receives FDA Fast Track Designation for Treatment of Retinitis Pigmentosa February 08, 2023 5578 read --> Endogena Therapeutics announced that the US FDA has designated the investigation of its drug EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Tr … frequent communication and more rapid regulatory review of the future new drug application for EA-2353. Matthias Steger, PhD, MBA, CEO of Endogena, said: “This acknowledgement by the FDA of the potential of EA-2353 for RP gives hope for patients living with this devastating degenerative disease. It is a significant milestone for our company, our investors, and gives recognition to our dedicated team at Endogena, who have been working for the past six years to reach thi … Wet AMD Treatment 2959 read FDA Accepts Outlook Therapeutics’ Biologics License Application for ONS-5010 in Wet AMD 3109 read Ophthalmologists Report a Fungal Endophthalmitis Outbreak After Cataract Surgery in S. Korea 3178 read DORC Receives FDA Clearance for Eva Nexus System 5496 read Aurion Biotech's NDA for Corneal Endothelial Disease Gets Approval in Japan 3771 read Categories Breaking News (226) Industry News (964) Ophthalmic Blog (351) Ophthalmic Research News (403) Re … ces, and practice management. COMPANY About Us Advertise Subscribe Write for Us Submit Press Release Feed LEGAL Cookies Term of Use Privacy Policy CATEGORIES Breaking News Industry News Ophthalmic Blog Ophthalmic Research News Ophthalmology Glossary PREPARED AND PUBLISHED BY Website: www.exon-trading.com Email: [email protected] 8th Floor, On Hing Building, 1 On Hing Terrace – Hong Kong CONTACT US [email protected] Categories Breaking News Industry … Blog Ophthalmic Research News Write for Us Spotlight TV Ophthalmology Glossary Submit Press Release
endogena therapeutics – endogena.com Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact ENDOGENA THERAPEUTICS is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders. Technology the vision Endogena Therapeutics’ approach for endogenous regenerative medicine will resu … and Tokyo – DEFTA Healthcare Technologies, the firm’s newly formed fund, invests in seed and early stage companies developing advanced therapeutics and digital health in the USA, Japan, Israel, and beyond – the current investments in healthcare include endogena therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA Partners also supports the annual World Alliance Forum in San Francisco, a premier, international conference focus … g pre-approval access for patients with no alternative treatment options should submit their requests to [email protected] . We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 10 business days after receipt. ETIENNE BINANT Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than 100 fundraisings in th … Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project. Jason Charish As Endogena Therapeutic’s Director of Translational Medicine, Jason Charish has experience managing the analysis, interpretation and presentation of clinical data from first-in-human trials, assisting in the design of future clinical trials and preparing scientific and regulatory documents key for moving projects forward. He is passionate about
Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions July 13 th , New York, NY Poignantly crafted from the clearest crystal, the Retina Innovation Award that now claims pride of place in Endogena Therapeutics’ trophy cabinet represents how far the company has come in developing a poten … t, where Endogena Therapeutics’ CEO, Dr Matthias Steger, was presented with the award by the summit’s co-chair, Dr John S. Pollack. Dr. Matthias Steger CEO Endogena Therapeutics with summit co-chair Dr. John S. Pollack “This award is recognition for the determined work of our team at Endogena now that our groundbreaking potential treatment has entered the clinic. Importantly, it represents new hope for patients with RP”, commented Matthias. A total of … clinical data at the event, with Endogena receiving the Retina Innovation Award in recognition for its lead product, EA-2353, a photoreceptor regeneration treatment for RP. EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can hence potentially preserve or restore visual function. This gene-independent treatment approach has significant advantages in RP,
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
endogena therapeutics – endogena.com Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact ENDOGENA THERAPEUTICS is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders. Technology the vision Endogena Therapeutics’ approach for endogenous regenerative medicine will resu … and Tokyo – DEFTA Healthcare Technologies, the firm’s newly formed fund, invests in seed and early stage companies developing advanced therapeutics and digital health in the USA, Japan, Israel, and beyond – the current investments in healthcare include endogena therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA Partners also supports the annual World Alliance Forum in San Francisco, a premier, international conference focus … g pre-approval access for patients with no alternative treatment options should submit their requests to [email protected] . We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 10 business days after receipt. ETIENNE BINANT Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than 100 fundraisings in th … Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project. Jason Charish As Endogena Therapeutic’s Director of Translational Medicine, Jason Charish has experience managing the analysis, interpretation and presentation of clinical data from first-in-human trials, assisting in the design of future clinical trials and preparing scientific and regulatory documents key for moving projects forward. He is passionate about
Financial Targets for the Sponsee and the Sponsor in the Restoration/Recovery of the Historical and Architectural Heritage | Springer Nature Link Skip to main content Advertisement Account Menu Find a journal Publish with us Track your research Search Saved research Cart Home New Metropolitan Perspectives Conference paper Financial Targets for the Sponsee and the Sponsor in the Restoration/Recovery of the Historical and Architectural Heritage Conference paper Open Access First Online: 25 July 2020 pp 155–165 Cite this conference paper You have full access to this open access conference paper D … ral companies are interested in sponsoring the restoration of the monument, the application of the model makes it possible to determine which company would be most suitable to sign the sponsorship contract. L. Dolores, M. Macchiaroli and G. De Mare—Contributed equally to this work. You have full access to this open access chapter, Download conference paper PDF Similar content being viewed by others The Estimation of the Optimal Level of Productivity for Sponsors in the … It follows that Administrations are unlikely to maximise public return from the application of the instrument. To overcome the problem, when estimating the sponsorship fees , it’s assumed that the advertising return offered to the sponsor is a function of various parameters, some referring to the property to be enhanced (name of the designer, time of construction, architectural quality, relevance of the property to the community) and others characterizing the sponsorship acti … f this information to optimise the contractualization phase of the agreement. 3 Application and Results Below is the main information about the monument and its location. 3.1 The Monument and Location Don Tullio’s Fountain (see Fig. 2 ), located in the Villa Comunale, is one of the most characteristic fountains of ancient Salerno. It currently has a medium level of degradation caused by atmospheric agents and human action. Fig. 2. Don Tullio’s Fountain (own elaboration) and t … ip in the year under review. Assuming therefore that it accepts the sponsorship proposal of the Municipality of Salerno we can put S = 1 and sS = € 180,000. Differently, Enterprise B in the year of analysis has already invested € 12,000 in sponsorships, that is about 7% of the amount requested by the Municipality of Salerno. If you also accept th
Actuate Therapeutics, Inc. Form 10-K false 2024 FY 0001652935 0001652935 2024-01-01 2024-12-31 0001652935 2024-06-30 0001652935 2025-03-10 0001652935 2023-01-01 2023-12-31 0001652935 2024-10-01 2024-12-31 0001652935 2024-12-31 0001652935 2023-12-31 0001652935 ACTU:RedeemableConvertiblePreferredStocksMember 2022-12-31 0001652935 us-gaap:CommonStockMember 2022-12-31 0001652935 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001652935 us-gaap:RetainedEarningsMember 2022-12-31 0001652935 2022-12-31 0001652935 ACTU:RedeemableConvertiblePreferredStocksMember 2023-12-31 0001652935 us-gaap:CommonSto … eding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth compa … ily affect individuals less than 18 years of age. If, in the future, a New Drug Application (“NDA”) for elraglusib for the treatment of Ewing sarcoma is approved by the FDA, we may be eligible to receive a Priority Review Voucher (“PRV”) that could be utilized by us or potentially sold to another company for its use.         5       Our Pipeline and Development Timeline   Our initial focus is on the development o … Actuate collaborated with Dr. Colin Weekes to obtain Lustgarten Foundation grant support for the IIT currently being run at MGH. Actuate provides financial and resource support for IITs in exchange for rights to the trial data but Actuate has no control over the design, conduct or timeline of an IIT.   · Advance our lead product candidate, elraglusib, by obtaining regulatory development incentives to accelerate path to approval.  One of our strategic objec … 2028, not including any Patent Term Extension (“PTE”), which we may apply for under Title II of the Drug Price Competition and Patent Term Restoration Act of 1984 (“Hatch-Waxman”), 35 U.S.C. §156. The following summarizes the key terms set forth in the UIC License Agreement.          25  
EA-2353 has the potential to reverse the loss of vision in patients with Retinitis Pigmentosa – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact EA-2353 has the potential to reverse the loss of vision in patients with Retinitis Pigmentosa Prev Previous Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye Next Michael Lai joins Endogena as Medical Director Next Contact endogena therapeutics inc.
Enamine and Endogena Therapeutics – a Successful, Multi-Year Drug Discovery Collaboration - Enamine Building Blocks Building Blocks Catalog MADE Building Blocks Fast MADE Building Blocks Functional Classes MedChem Highlights DEL-compatible Scaffolds Building Block Sets for Library Synthesis Linkers for Linkerology Catalysts and Ligands Reagents for Synthesis Bioorthogonal Reagents Enamine Basicity-Tuning Kits Linkers for MOFs and COFs Late-Stage Functionalization Kit Compound Libraries AI-enabled Libraries Molecular Glues Diversity Libraries Targeted Libraries Bioactive Libraries Fragment Libr
Endogena Updates Skip to main content search About Us Contact Us Mission & History Staff & Board Scientific Advisory Committee Who We Work With USH Partners Community Collaborators Coalition Newsroom Grounded in Science Newsletters Coalition in the News Financials USH Foresight Awards Research Current USH Research Science News Get Genetic Testing Data Collection USH Talks and Presentations USH Talks Library Connections Conference Presentations Past Symposium Presentations Past USH Research Presentations Resources What is Usher syndrome? Living with Usher Syndrome USH Ambassadors Just f
Endogena Therapeutics to start clinical stage with treatment for blindness Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Se
Endogena Therapeutics Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib mar … Oct. 24, 2023 Endogena Therapeutics Inc. has received FDA clearance of its IND application for EA-2351 for geographic atrophy, an advanced form of age-related macular degeneration (AMD). Read More Endogena heads for clinic with RP regenerative medicine tech after $29M series A Dec. 13, 2021 By Richard Staines Endogena Therapeutics Inc., of San Francisco, has raised another $20 million in a series A funding round to progress a regenerative medicine that could use stem cells t
Endogena Therapeutics RP treatment gets FDA fast track Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sect … finds key genes for potential treatments Angel Pharma announces approval of IND application for clinical trial of mupadolimab Latest Articles “It’s time to Act”: EU biotech to undergo major changes De-risking neurology drug development with better mouse models Roche, a company built on oncology and diagnostics reinventing its pipeline Bronchiectasis treatment after brensocatib: where the field goes next Subscribe to our newsletter Get the latest biotech news directly to your
Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration | Business Wire Sök nyheter Abonnera Sök pressrum Om tjänsten Bli kund Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration 19.4.2023 09:00:00 CEST | Business Wire | Press Release Share Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage biotech company focused o … sponsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve custom … nance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro Incyte Announce … ion will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP 26.6.2026 12:49:00 CEST | Press Release Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positiv
FDA Fast Track Designation for retinitis pigmentosa treatment - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antib
BioTalent Behind the Talent details-tag#clickAway keydown.esc@window->details-tag#close:passive" class="group"> Home Episodes About BioTalent Behind the Talent Home Episodes About + Follow BioTalent Behind the Talent We like to discuss all things Life Sciences related. We are BioTalent, we host networking and knowledge-building events, webinars and podcasts within the Life Sciences sector. If you're looking for a way to stay up to date in the pharmaceutical world then have a listen to our podcast series. The series brings together market-leading experts. We cover topics from diversity to innov
Retinitis pigmentosa drug proved safe in Phase I/IIa study - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodi
Small-Molecule-Directed Endogenous Regeneration of Visual Function in a Mammalian Retinal Degeneration Model | Endogena Therapeutics, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking
Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration | Business Wire Tiedotteet Tilaa tiedotteita Julkaisijat Tietoa palvelusta Osta kertatiedote Enamine and Endogena Therapeutics – a successful, multi-year drug discovery collaboration 19.4.2023 10:00:00 EEST | Business Wire | Press release Share Enamine Ltd., a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments, and screening compounds, gave an update of its long-standing research collaboration with Endogena Therapeutics AG, a clinical-stage bio … sponsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve custom … nance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro Incyte Announce … ion will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP 26.6.2026 13:49:00 EEST | Press release Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positiv
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa San Francisco, USA; Toronto, Canada; Zürich, Switzerland, February 6, 2023 Endogena Therapeutics Inc. , a clinical-stage biotech company focused on the development of endogenous regenerative m … opment of EA-2353 and allow more rapid regulatory review of the future new drug application. Matthias Steger, PhD, MBA, CEO of Endogena, said : “This acknowledgement by the FDA of the potential of EA-2353 for RP gives hope for patients living with this devastating degenerative disease. It is a significant milestone for our company, our investors, and gives recognition to our dedicated team at Endogena, who have been working for the past six years to reach this point.” Endogen
Endogena starts clinical trials for regenerative treatment for blindness News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout Endogena starts clinical trials for regenerative treatment for blindness Success Please login or register 18.07.2022 Zurich and San Francisco-based Endogena Therapeutics has treated the first patient in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa, one of the leading causes of inherited blindne … Register for more services Create your personal archive Get the Newsletter Set award alarms Partners Contributors Supporters Supporters News Startup Media House Pinboard News archive Newsletter archive Editorials Directories Awards Grants & Loans Jobs Investors Facts Initiatives Archive News Interviews Editorials Magazines Swiss Venture Capital Report Top 100 Startup Magazine Gründen Swiss Startup Radar Calendar Events Trainings Most viewed Interactive Login Register Twitter … inings Most viewed Interactive Login Register Twitter Get your personal archive Submit an event Submit special offer Contact us About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa San Francisco, USA; Toronto, Canada; Zürich, Switzerland, May 4, 2023 Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed pati
Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa San Francisco, USA; Toronto, Canada; Zürich, Switzerland, April 5, 2023 Endogena Therapeutics Inc ., a clinical-stage biotech company focused on the develo
Endogena Therapeutics completes enrollment early for its Phase 1/2a trial of EA-2353 for retinitis pigmentosa | Modern Retina --> --> News All News Blogs Media All Videos Case-Based Roundtable Series Eichenbaum Acorns Expert Interviews Eyeviews Insights Medical World News Podcasts Rapid Readouts The Retina TL;DR The Wills Retina Report Viewpoints Conferences Conference Coverage Conference Listing Publications Modern Retina Digital Edition Supplements And Featured Publications More Resources Between the Lines CME/CE EYLEA 8mg for nAMD and DME Treatment Sponsored Resources Partners Subscribe My
Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle,Washington, US. – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4th, 2024, in Seattle,Washington, US. Zürich, Switzerland, May 4, 2024 Matthias Steger was invited to present at the Ophthalmology Innovation Summit (OIS) on May 4 th , 2024, in Seattle, Washington, US.
Inspiring to have Matthias Steger, speaking at our recent conference in Montreux - Swiss Healthcare Licensing Group Home About us Annual conferences Our initiatives Good Partnering Practices Start-up Initiative Webinars Networking Events Join us News Contact Visit our LinkedIn Inspiring to have Matthias Steger, speaking at our recent conference in Montreux Home » Inspiring to have Matthias Steger, speaking at our recent conference in Montreux It was very inspiring to have Matthias Steger PhD, MBA , CEO of Endogena Therapeutics, Inc. speaking at our recent conference in Montreux on ¨Endogena Th
Endogena Therapeutics, Inc. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Organization Endogena Therapeutics, Inc. endogena.com Company Details Description Endogena is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of … l of Lucerne, Switzerland. In 2012 he was awarded the George and Rosalie Hearst Fellowship at the University of California, San Francisco, USA to undertake a clinical fellowship under the mentorship of Professor Jacque Duncan. Thereafter he worked for a Swiss private eye clinic before having been granted 2016 the position of vitreoretinal fellow at Sir Charles Gairdner Hospital in Perth, Australia, where he trained under the supervision of Professor Ian Constable. In 2019, Dr … rvision of Professor Ian Constable. In 2019, Dr. Menghini completed an academic fellowship with focus on retinal gene therapy at the University of Oxford, UK under the mentorship of Professor Robert MacLaren. As an honorary clinical research associate of the University of Oxford, he continues to be involved scientifically through various joint collaborations. Through his continuous academic achievements Dr. Menghini has recently received the venia legendi at the University of … l of Lucerne, Switzerland. In 2012 he was awarded the George and Rosalie Hearst Fellowship at the University of California, San Francisco, USA to undertake a clinical fellowship under the mentorship of Professor Jacque Duncan. Thereafter he worked for a Swiss private eye clinic before having been granted 2016 the position of vitreoretinal fellow at Sir Charles Gairdner Hospital in Perth, Australia, where he trained under the supervision of Professor Ian Constable. In 2019, Dr … rvision of Professor Ian Constable. In 2019, Dr. Menghini completed an academic fellowship with focus on retinal gene therapy at the University of Oxford, UK under the mentorship of Professor Robert MacLaren. As an honorary clinical research associate of the University of Oxford, he continues to be involved scientifically through various joint co
Gisbert Schneider - Scientific Advisor at Endogena Therapeutics | The Org Platform Enrich Pricing Log in Sign up Endogena Therapeutics Gisbert Schneider Unverified Gisbert Schneider Scientific Advisor Contact Gisbert Schneider is a Scientific Advisor at Endogena Therapeutics. Gisbert has also worked as a Guest Professor at Université de Strasbourg, Full Professor of Chem- and Bioinformatics at Goethe University, and Editor In Chief at Wiley-Blackwell. Additionally, they have held positions as a Lecurer in Biochemistry & Bioinformatics at The University of Freiburg, Research Scientist &am
#swisshlg #biopharma #dealmaking #innovation #networking #endogena | Swiss HLG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Ag
Endogena closes dose escalation in retinitis pigmentosa trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Serv … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Home Copy – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact ENDOGENA THERAPEUTICS is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders. Technology the vision Endogena Therapeutics’ approach for endogenous regenerative medicine will result … and Tokyo – DEFTA Healthcare Technologies, the firm’s newly formed fund, invests in seed and early stage companies developing advanced therapeutics and digital health in the USA, Japan, Israel, and beyond – the current investments in healthcare include endogena therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA Partners also supports the annual World Alliance Forum in San Francisco, a premier, international conference focus … g pre-approval access for patients with no alternative treatment options should submit their requests to [email protected] . We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 10 business days after receipt. ETIENNE BINANT Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than 100 fundraisings in th … Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project. Jason Charish As Endogena Therapeutic’s Director of Translational Medicine, Jason Charish has experience managing the analysis, interpretation and presentation of clinical data from first-in-human trials, assisting in the design of future clinical trials and preparing scientific and regulatory documents key for moving projects forward. He is passionate about … tion systems, staffing and development of accounting teams, and development and application of accounting policies and procedures. Mr. Pollot is a CPA and holds a Bachelor of Business Administration in Accounting from the University of Oklahoma . Michelle Widmann Michelle Widmann has over 20 years of experience overseeing clinical trials. Her bac
#oisretinainnovationsummit #endogena #regenerativemedicine #oisretina #innovationsummit #visionrestoration #biotechinnovation #healthcaresummit | Endogena Therapeutics, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject … ecial place in our hearts, as we were proud recipients of the Retina Innovation Award crystal in New York City two years ago! To discover our latest breakthroughs from our clinical trials targeting Retinitis Pigmentosa (RP) patients and learn about our progress in treating dry age-related macular disease (AMD), meet us at the summit. Don't miss your chance to gain strategic insights and network with key players in the field of regenerative medicine in ophthalmology. We can't
First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness Zürich, Switzerland, May 3, 2024 First data showing preliminary evidence of efficacy
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa Zürich, Switzerland and Toronto, Canada; 12th July 2022 Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase … Lai joins Endogena as Medical Director Next Endogena receives Retina Innovation Award at event showcasing new therapies for eye conditions Next Contact endogena therapeutics inc. 111 pine street san francisco | ca 94111 usa +1 (415) 594-0594 Contact endogena therapeutics ag binzmühlestrasse 170 d 8050 zürich switzerland [email protected] Linkedin Youtube Linkedin Youtube members of
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas — Foundation Fighting Blindness Stay up to date on the latest Foundation news and research. Join Today! Close Skip to main content Skip to footer Foundation Fighting Blindness homepage Search My Chapter: Arizona Atlanta Austin Baltimore Charlotte Chicago Cincinnati/Northern Kentucky Cleveland Colorado Columbus Dallas-Fort Worth D.C. Metro Eastern Michigan Fort Wayne Greater New York Hampton Roads/Virginia Beach Houston Indianapolis Jacksonville Kansas City Las Vegas Los Angeles Maine Miami Naples Nashvil … Region Washington Wisconsin View Chapter Donate Give Monthly Menu Close Search Submit Understanding Vision Loss Understanding Vision Loss Vision Loss Glossary Retinal Education Videos Achromatopsia Bardet-Biedl Syndrome (BBS) Best Disease Choroideremia CRB1-Associated Diseases Geographic Atrophy (GA) Leber Congenital Amaurosis (LCA) Macular Degeneration PRPH2-Associated Diseases Retinitis Pigmentosa Refsum Disease Stargardt Disease Thyroid Eye Disease Usher Syndrome X-Linked … um VISIONS (United in Vision) Conference Awareness Calendar United In Vision RD Fund Genetic Testing For ECPs About Mission & History Board of Directors Leadership Strategic Council Scientific Advisory Board National Trustees Corporate Partners Financials & Governance Annual Reports Careers Contact Ways to Give Credit Card, ACH & PayPal Tribute Donations Legacy Giving Donor Advised Funds Stock Donations Crypto Donations IRA Charitable Rollover Join a VisionWalk Ho
Beyond Biotech podcast 8: Biotech Growth Trust, DSV, Endogena Therapeutics, eureKARE Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding w
Approachable Regenerative Medicine, with Matthias Steger, PhD, Endogena Therapeutics | Ophthalmology Innovation Source | ExSight Ventures LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking C
endadmin – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Author: endadmin First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness Zürich, Switzerland, May 3, 2024 First data showing preliminary evidence of efficacy were presented at the Retinal Cell and Gene Therapy Innovation Summit organized by the Foundation Fighting Blindness (May 3rd, Seattle, Washing
Approachable Regenerative Medicine, with Matthias Steger, PhD, Endogena Therapeutics | Ophthalmology Innovation Source Skip to content Follow our social pages & join our growing community Linkedin Youtube X-twitter Menu HOME EVENTS OIS Retina – July 14, 2026 OIS Ignite – March 11, 2027 OIS XVI – March 12-13, 2027 PAST EVENTS PODCASTS SPONSORSHIP Approachable Regenerative Medicine, with Matthias Steger, PhD, Endogena Therapeutics PODCAST EPISODE 381 Click here to watch the video version of this podcast. Endogena Therapeutics has developed a novel approach to regenerative medic … to share in early 2024. It’s also submitting an investigational new drug (IND) application for an age-related macular degeneration treatment later this month. Listen to the podcast today to discover: • The “serendipitous discoveries” that moved Dr. Steger’s career from applied science to financial analyst to regenerative medicine start-up cofounder. • The stem cell approach that Dr. Steger and team are applying to Endogena products and how it differs from implanted stem cell … e RP product and what happens after dosing is complete. • How Endogena plans to fund its current and upcoming programs. Where has the funding come from to date? And for upcoming clinical trials? Resources Endogena Therapeutics https://endogena.com Firas Rahhal, MD https://ois.net/firas-m-rahhal-md © 2026 · Ophthalmology Innovation Summit · Linkedin Youtube X-twitter Scroll To Top
Las grandes farmacéuticas aceleran la carrera por los fármacos descubiertos con IA - SWI swissinfo.ch Ir a Portada Ir a Navegación Ir a la navegación horizontal Ir a la selección de idioma Ir a Contenido The Swiss voice in the world since 1935 Página principal Quiénes somos Buscar Secciones Geopolítica Democracia Ciencia Sociedad Economía Noticias de Suiza Vídeos Debates Gran Formato Opinión Newsletters Edición especial Preguntas a Swissinfo Guía de Suiza Síganos Why you can trust Swissinfo es English en Deutsch de Français fr Italiano it Español es Português pt 日本語 ja العربية ar 中文 zh Русский … Steger, quien, para seguir desarrollando los dos candidatos a fármaco, en 2016 fundó con Schneider la empresa emergente Endogena, con oficinas en Zúrich y San Francisco. “Los algoritmos pueden ver patrones que no son visibles al ojo humano”, dice. La inversión en IA se ha visto impulsada por su potencial para descubrir nuevos candidatos a fármacos en una fracción del tiempo y del coste de los enfoques tradicionales. En la última década, se han invertido más de 18.000 millone
Các tập đoàn dược phẩm Thụy Sỹ đầu tư vào AI - Tuổi Trẻ Online Podcast YouTube Cần biết Rao vặt Xin chào, Cài đặt tài khoản Tin đã lưu Bình luận của bạn Lịch sử giao dịch Dành cho bạn Vào Tuổi Trẻ Sao Thoát Tuổi Trẻ Sao Đăng xuất Đặt báo Đăng ký Tuổi Trẻ Sao Vào trang Tuổi Trẻ Sao Mới nhất Xem nhiều Video Thời sự Thế giới Pháp luật Kinh doanh Công nghệ Xe Du lịch Nhịp sống trẻ Văn hóa Giải trí Thể thao Giáo dục Nhà đất Sức khỏe Giả thật Bạn đọc Tất cả chuyên mục Đóng Video Mới nhất Tin nóng Trực tiếp Thú vị Xem thêm... Thế giới Đời thường Bạn có biết Thể thao Giải trí Hài hước 30S Nóng Góc nhì … ớng Theo gương Bác Khám phá Yêu Xem thêm... Nhân vật Việc làm Tuổi Trẻ Start-Up Award Văn hóa Nhân vật Sàn diễn Sách Đời sống Xem thêm... Ẩm thực Giải trí Nghe gì hôm nay Âm nhạc Điện ảnh TV Show Xem thêm... Thời trang Hậu trường Thể thao Bóng đá Bóng rổ Võ thuật Khỏe 360 Xem thêm... Video SEA Games 31 Tin tức Người hâm mộ Bình luận Thể thao vui Các môn khác Lịch thi đấu Bóng chuyền Giáo dục Tuyển sinh Nhịp sống học đường Chân dung nhà giáo Du học Xem thêm... Câu chuyện giáo
Các tập đoàn dược phẩm Thụy Sỹ “chạy đua” với AI Thứ 7, Ngày 27/06/2026 Rss Tin mới 22:46 Động đất tại Venezuela: Con số thiệt mạng tăng lên 589 người - Cộng đồng quốc tế khẩn trương tiếp viện 21:48 Sửa đổi, bổ sung một số quy định về hoạt động khuyến mại 21:47 YADEA ra mắt Omee, bắt tay Be Group thúc đẩy thị trường xe máy điện Việt Nam 21:38 Điểm tin kinh tế Việt Nam nổi bật ngày 26/6/2026 21:38 PETROCONS mời hợp tác tái cấu trúc Tổng thể Tổng Công ty Thời sự Truyền thông chính sách Bình luận Kinh tế Việt Nam Kinh tế Thế giới Doanh nghiệp Chuyển độ
Endogena Therapeutics - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Sci … (FDA) has granted clearance for Endogena’s Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. Read More 27 October 2023 #News #Regulatory #Artificial intelligence (AI) #Endogena Therapeutics #Ophthalmology #Phase I trial #Phase II trial #Retinitis pigmentosa Retinitis pigmentosa drug proved safe in
Matthias Steger, PhD | Ophthalmology Innovation Source Skip to content Follow our social pages & join our growing community Linkedin Youtube X-twitter Menu HOME EVENTS OIS Retina – July 14, 2026 OIS Ignite – March 11, 2027 OIS XVI – March 12-13, 2027 PAST EVENTS PODCASTS SPONSORSHIP Matthias Steger, PhD Co-Founder & CEO Endogena Biography STAY UP TO DATE WITH OIS STAY UP TO DATE WITH OIS get the latest news & exclusive content! get the latest news & exclusive content! SUBSCRIBE TO THE OIS WEEKLY NEWSLETTER SUBSCRIBE TO THE OIS WEEKLY NEWSLETTER © 2026 · Ophthalmology
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
EyeWorld Weekly, February 10, 2023 - EyeWorld Skip to content Search... Submit search Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME Programs & Projects Corporate Replay Corporate Educational Events Supplements Menu Close Sections ASCRS News Cataract Refractive Cornea Glaucoma Practice Management Issues Current issue Issue archives Online Exclusives EyeWorld Weekly Latest EyeWorld Weekly EyeWorld Weekly archives Sign up Non-CME … or glaucoma BLA resubmission received by FDA for wet AMD treatment Company news Grant opportunity ASCRS news and events EyeWorld article of the week Read EW Weekly Archives Get the latest ophthalmology news delivered to your inbox every Friday. Sign up for EW Weekly Archives EyeWorld articles Supplements EyeWorld Daily News EyeWorld Weekly EyeWorld Onsite EyeWorld About Contact us ASCRS.org ASCRS Marketing & Sales Partnerships EyeWorldOnsite.org Search © 2026 EyeWorld Ne
LLM Info Page - Integral BioSystems Skip to content Home About Us History, Business Model & Mission Quality Statement Management Team Careers CRO Services Focus Expertise & Approach Expertise in Delivery Routes Ophthalmic Drug Delivery Injectable Drug Delivery Rectal Drug Delivery Transdermal Drug Delivery Sublingual Drug Delivery Oral Drug Delivery Intranasal Drug Delivery Inhalation Drug Delivery Otic Drug Delivery Expertise in Analytics Facilities & Capabilities Collaborations Lipid Nanoparticles (LNP) Cyclodextrins Microencapsulation Nano- & Micro-Crystallization Licens
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview M … ;to IND. Subject to U.S. Food and Drug Administration (FDA) approval of its IND application, Endogena's lead program, EA-2353, will enter first-in-human trials in the first half of 2022. In May, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for EA-2353 which provides benefits including market exclusivity once approved, exemption of FDA application fees, and tax credits for qualified clinical trials. EA-2353 is an endogenous photoreceptor regenera … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
%PDF-1.6 %���� 1495 0 obj > endobj 1528 0 obj >/Filter/FlateDecode/ID[ ]/Index[1495 66]/Info 1494 0 R/Length 140/Prev 10853425/Root 1496 0 R/Size 1561/Type/XRef/W[1 3 1]>>stream h�bbd```b`��"�$�I0[ Dr���. �ILf�I �x�-&��I^$0�L���� ��D���H�6)�DjIF�E`���b��s@$�>�� >stream h��}Pwǟ�MBBI���jb%g�R��5�K��vB �Z`���� �Z��`řH}���/h}��� -�)�7�'M v쩵R�+�^�v7�z7ӛ�����$���{���ͳ;� (uC@h!H��Cl*�n��ϧ�$�In�!+B F��U,�(�D�J����z���vS����>�o� �V��TJh���V��)c�I��y��C9�vA���ēx�y��7�ة���?;&; G���J�=i� [��f�|��U��m��xC�z7_��=�u���}���.3��]�=�[Szq����v�c���� [vO�e� … }yn-6���{�wz`����֜a�����7������ '_ pV�� endstream endobj 1523 0 obj >stream application/postscript Greg Nielsen SBT-Logo-TM-4c-pos.eps Adobe Illustrator CS2 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 2005-12-14T22:41:49+01:00 uuid:24EBF3E16E8511DA9E4086E538E29E18 uuid:24EBF3E26E8511DA9E4086E538E29E18 endstream endobj 1524 0 obj >>>/Subtype/Form/Type/XObject>>stream H�2P��*�2PAC�l.}�`��b.#=Cs#=#s csC= ] ��H�(�+�+� �n� endstream endobj 1525 0 obj >/ProcSe … ����J�`� �L|0�@��#���24��[w���AX������ �u� endstream endobj 3 0 obj >stream application/pdf LONZA_LOGO_MAIN-BLK 2021-01-28T18:30:46Z 2021-01-28T18:30:46Z 2021-01-28T18:30:46+01:00 Adobe Illustrator 25.1 (Windows) uuid:a3de2334-99ae-43ee-9bbd-741f79caa74a xmp.did:4b30f76e-9211-bb47-ab33-a3600ddfe9ba uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:9963990e-1bd9-b545-9ca6-06946215f430 xmp.did:9963990e-1bd9-b545-9ca6-06946215f430 uuid:5D20892493BFDB11914A8590D31508C8 … 6215f430 2021-01-28T18:06:09Z Adobe Illustrator 25.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:4b30f76e-9211-bb47-ab33-a3600ddfe9ba 2021-01-28T18:13:17Z Adobe Illustrator 25.1 (Windows) / Print AIRobin Document False False 1 134.166337 51.249506 Millimeters Cyan Magenta Yellow Black Default Swatch Group 0 White RGB PROCESS 255 255 255 Black RGB PROCESS 29 29 27 CMYK Red RGB PROCESS 227 6 19 CMYK Yellow RGB PROCESS 255 … ) 2024-01-31T09:39:48+01:00 2024-04-10T08:57:56+02:00 2024-04-10T08:57:56+02:00 application/vnd.adobe.photoshop 4 Coated FOGRA39 (ISO 12647-2:2004) xmp.iid:c6d133e2-6c37-4c43-a5c7-2d2003c911c9 adobe:docid:photoshop:cbdeaaad-f9b2-a14f-b3b0-3fa9427c4f33 xmp.did:31c8d117-0238-4925-9f3f-74244c25ee44 created xmp.iid:31c8d117-0238-4925-9f3f-74244c25ee4
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Endogena Therapeutics holds investor call and gives update on Retinitis Pigmentosa Clinical Trial – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Therapeutics holds investor call and gives update on Retinitis Pigmentosa Clinical Trial Zürich, Switzerland, February 7, 2024 Listen to a testimonial from one of our principal investigators Dr. Victor Gonzalez. Prev Previous Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment Next Matthias
%PDF-1.6 %���� 1 0 obj >/OCGs[30 0 R]>>/Pages 3 0 R/Type/Catalog>> endobj 2 0 obj >stream application/pdf ELSF Agenda 2023-03-02T09:33:03+01:00 2023-03-02T09:33:03+01:00 2023-03-02T09:33:03+02:00 Adobe Illustrator 26.5 (Windows) 256 132 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgAhAEAAwER
AAIRAQMRAf/EAaIAAAAHAQEBAQEAAAAAAA
Endogena Therapeutics Inc. | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026
Endogena Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 05 Mar 2026 Endogena Therapeutics, Inc. Startups | Holding Company | 2016 | California, United States | < 10 | www.endogena.com Startups | Holding Company | 2016 | California, United States | < 10 | www.endogena.com Last update 05 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Endogena is a biotechnology firm that specializes in creating regenerat … the following patents related to its AAV-based retinal gene therapy: US patent application relating to cell transfection improvements for AAV vector production. We expect that any patents issued from this application will expire in 2038, excluding any potential patent term extension or adjustment. A US patent application relating to improvements in AAV vector purification. It expects that any patent from this application will expire in 2038, excluding any potential patent te … ene therapy vector Spark Therapeutics holds exclusive licenses for three patent application families from CHOP, covering scalable methods for manufacturing high-purity gene therapy vectors. The first patent family pertains to the production of Spark's product candidates, including those under its collaboration with Pfizer. Patents from this family have been granted in the United States, Australia, and Mexico, with expiration dates in 2021, not accounting for any potential ext … ation (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351. This innovative compound offers hope to patients battling geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The eagerly awaited first-in-human study is set to commence in 2024. This milestone marks the company's second program to progress into clinical trials, building on the mom … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Hitting the century mark: 100 candidates and counting Topics AMD Clinical Trial Closeup Coding & Medicare DME Editor's Page Genetics Imaging & Diagnostics News RVO Stem Cells Surgical Pearl Video Surgical Techniques & Tools Uveitis Vitrectomy Current Issue Archive CME Hitting the century mark: 100 candidates and counting Geographic atrophy continues to be the fastest-growing area of interest, and new entries double the number of dropouts. By Richard Mark Kirkner February 27, 2024 Seventh Annual Pipeline Report Take-home points This year’s listing includes … look Therapeutics) The FDA last year didn’t approve the biologics license application (BLA) for this ophthalmic formulation of Avastin. In December, Outlook submitted a special protocol assessment request with the FDA seeking confirmation that the NORSE EIGHT trial would fulfill the FDA’s requirement for a second clinical trial in nAMD. Outlook says it expects a response early this year. NORSE EIGHT would enroll about 400 patients and compare ONS-5010 1.25 mg with … al testing in 2024. Aldeyra says it expects to file an investigational new drug application this year with the U.S. Food and Drug Administration for a Phase I/II clinical trial in dry AMD patients with dark-adaptation deficit. ANX007 (Annexon Biosciences). ANX007 is a C1q and classical complement inhibitor. Annexon says it’s prepared to move ahead with the ARCHER II Phase III registration program that includes using, for the first-time, the prevention of  … (n=465, NCT05407636) trials in nAMD are expected to support a biologics license application (BLA) in 2025 or 2026. EXG102-031 (Exegenesis Bio). EXG102-031 is an injectable recombinant AAV-based gene therapy that aims to express a therapeutic fusion protein that binds or neutralizes all known subtypes of VEGF and angiopoietin-2 (ang-2). Two separate clinical trials in nAMD last year started recruiting patients: a Phase I U.S. trial (n=6) known as Everest; and a Phase I/I … 8 (Amgen). The U.S. Food and Drug Administration accepted the biologics license application (BLA) for ABP 938. Final analysis from a Phase III study in neovascular age-related macular degeneration (n=566, NCT04270747) confirmed no clinically meaningful differences in efficacy between the biosimilar and reference product. A separate Phase III tria
Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye – endogena therapeutics Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye We are thrilled today to announce that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treat
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
endogena therapeutics – endogena.com Skip to content Technology Pipeline News Press People Partners Careers Contact Menu Technology Pipeline News Press People Partners Careers Contact ENDOGENA THERAPEUTICS is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. Our approach has the potential of a paradigm shift to treat degenerative conditions related to aging and genetic disorders. Technology the vision Endogena Therapeutics’ approach for endogenous regenerative medicine will resu … and Tokyo – DEFTA Healthcare Technologies, the firm’s newly formed fund, invests in seed and early stage companies developing advanced therapeutics and digital health in the USA, Japan, Israel, and beyond – the current investments in healthcare include endogena therapeutics, Orig3n, Two Pore Guys, Lifeguard Health Networks, and Graftworx. DEFTA Partners also supports the annual World Alliance Forum in San Francisco, a premier, international conference focus … g pre-approval access for patients with no alternative treatment options should submit their requests to [email protected] . We regularly monitor this mailbox and will use our best efforts to acknowledge each submitted request within 10 business days after receipt. ETIENNE BINANT Etienne’s career spans over 25 years of entrepreneurship and financing in the Healthcare (Biotech and Medtech) and IT spaces. Etienne has successfully led more than 100 fundraisings in th … Arts, he sits on the board of such established institutions as the Paris Opera Fund, or the Los Angeles Dance Project. Jason Charish As Endogena Therapeutic’s Director of Translational Medicine, Jason Charish has experience managing the analysis, interpretation and presentation of clinical data from first-in-human trials, assisting in the design of future clinical trials and preparing scientific and regulatory documents key for moving projects forward. He is passionate about
Research News | Monthly Updates | Fighting Blindness Canada --> Skip to main content Colour C C C C C --> Text T T --> ACCESSIBILITY TOOLS Board Portal --> Français Donate Menu Donate Home Eye Health Eye Diseases New Treatments & Clinical Trials Genetic Testing Newly Diagnosed Additional Resources Research Current Funded Research Previously Funded Research For Researchers Research Strategy Patient Registry About Us Who We Are Strategic Plan Your Impact Milestones Impact & Financial Reports Vision Health Partners Careers Our Stories Contact Us Get Involved Move for Sight Become a Fundraiser … e first potential treatment for Stargardt disease, with the company planning to submit the drug for approval to the US Food and Drug Agency in 2026. Stem Cells Show Promise to Restore Sight in dry AMD Results were published from an early-stage clinical trial testing a new stem-cell therapy for people with advanced dry age-related macular degeneration (AMD). Participants received a transplant of retinal pigment epithelial (RPE) cells, the cells that are damaged in dry AMD and … l cells, triggering a visual signal that’s sent to the brain. In a future human application, researchers say laser light could be delivered through a special pair of goggles. One advantage of this potential approach is that it would only require an injection and the use of the goggles—no complex surgery. While this is an exciting and innovative approach, it’s still early days. More research is needed before the technique can be considered for clinical trials. New Discovery Co … opment of related photoswitch molecules through a Restore Vision 20/20 Research Award to Dr. Richard Kramer (University of California Berkley). We look forward to sharing more information about the trial in the future. In other clinical trial news, GenSight Biologics announced early results from their Phase I/II clinical trial, testing the optogenetic therapy GS030 for advanced RP. This potential treatment uses a gene therapy approach paired with special goggles. So far nine … for Usher syndrome 2A (USH2A). ProQR is actively looking for a partner to help fund these programs and enable the launch of additional clinical trials to meet regulator recommendations. ProQR will work with clinical trial participants, including those in Canada, to try and offer them continued access to sepofarsen or ultevursen therapy. At Fight
Gene-Independent Therapeutic Approaches for Usher Syndrome Skip to main content search About Us Contact Us Mission & History Staff & Board Scientific Advisory Committee Who We Work With USH Partners Community Collaborators Coalition Newsroom Grounded in Science Newsletters Coalition in the News Financials USH Foresight Awards Research Current USH Research Science News Get Genetic Testing Data Collection USH Talks and Presentations USH Talks Library Connections Conference Presentations Past Symposium Presentations Past USH Research Presentations Resources What is Usher syndrome? Living … eural cells--for patients with RP. The trial is being funded by a $10.5 million grant from the California Institute for Regenerative Medicine. The study's principal investigator is Clive Svendsen, PhD, professor of Biomedical Sciences and Medicine and director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa As of October 15, 2024, Cl … S. FDA. September 3 , 2024 BlueRock Therapeutics announces FDA clearance of IND application for investigational iPSC-derived cell therapy OpCT-001 for the treatment of primary photoreceptor diseases BlueRock Therapeutics LP has announced that the U.S. Food and Drug Administration (FDA) has cleared OpCT-001, its investigational product, an induced pluripotent stem cell (iPSC)- derived cell therapy, through an Investigational New Drug (IND) application. January 23 , 2024 BlueRo
In the summer of 2022, Endogena... - Usher Syndrome Coalition Facebook Log In Usher Syndrome Coalition's Post Usher Syndrome Coalition April 21, 2023 · Shared with Public In the summer of 2022, Endogena launched its first dosing of its phase 1/2a study of EA-2353 in retinitis pigmentosa (RP). Endogena is attempting to activate stem cells in the retina with EA-2353, which takes a novel, small-molecule approach, with hopes of producing and replacing lost and damaged photoreceptors, the reason for loss of vision in Usher syndrome and retinitis pigmentosa. EA-2353 is designed to work independ
Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa July 12, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc. announced today that the first patient has been treated in a phase 1/2a clinical study of it … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena completes $8 million financing and extends Series A round to advance its novel treatments for neurodegenerative diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Endogena completes $8 million financing and extends Series A round to advance its novel treatments for neurodegenerative diseases January 28, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc., which discovers and develops endogenous regenerative medicines, today announced that it has suc … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Rejuveron Increases to Near-majority Stake in Endogena Through Funding $20m to Progress Treatments for Degenerative Diseases of the Eye December 13, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, today an … to IND. Subject to U.S. Food and Drug Administration (FDA) approval of its IND application, Endogena’s lead program, EA-2353, will enter first-in-human trials in the first half of 2022. In May, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for EA-2353 which provides benefits including market exclusivity once approved, exemption of FDA application fees, and tax credits for qualified clinical trials. EA-2353 is an endogenous photoreceptor regenera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa May 4, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has comp … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busines … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Endogena Completes Series A with Total Funding of $29 million to Progress Treatments for Degenerative Diseases of the Eye December 13, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc., an endogenous regenerative therapeutics company, today announced that its largest shareholder and lead … to IND. Subject to U.S. Food and Drug Administration (FDA) approval of its IND application, Endogena’s lead program, EA-2353, will enter first-in-human trials in the first half of 2022. In May, the U.S. Food and Drug Administration (FDA) granted orphan drug designation for EA-2353 which provides benefits including market exclusivity once approved, exemption of FDA application fees, and tax credits for qualified clinical trials. EA-2353 is an endogenous photoreceptor regenera … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job T … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa February 6, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc. announced today that the US Food and Drug Administration (FDA) has designated the invest … opment of EA-2353 and allow more rapid regulatory review of the future new drug application. Matthias Steger, PhD, MBA, CEO of Endogena, said : “This acknowledgement by the FDA of the potential of EA-2353 for RP gives hope for patients living with this devastating degenerative disease. It is a significant milestone for our company, our investors, and gives recognition to our dedicated team at Endogena, who have been working for the past six years to reach this point.” Endogen … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment October 24, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Endogena Therapeutics Inc., a pioneering biotech company dedicated to revolutionizing regenerative medicine, is proud to announce a significant achiev … ation (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351. This innovative compound offers hope to patients battling geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). The eagerly awaited first-in-human study is set to commence in 2024. This milestone marks the company's second program to progress into clinical trials, building on the mom … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Endogena Therapeutics | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance